DIAGNOSIS OF CUSHING’S SYNDROME; BIOCHEMICAL INVESTIGATIONS by Siddiqi, Ahmed Imran & Noor, Muhammad Usamah Bin
JOURNAL OF CANCER & ALLIED SPECIALTIES 1
REVIEW ARTICLE J Cancer Allied Spec 2017;3(4):2
DIAGNOSIS OF CUSHING’S SYNDROME: BIOCHEMICAL INVESTIGATIONS
Ahmed Imran Siddiqi1, Muhammad Usamah Bin Noor2
1North Manchester General Hospital, Manchester, UK, 2Manchester Royal Infirmary, Manchester University NHS 
Foundation Trust, Manchester, UK
Received: 18 December 2017 / Accepted: 29 December 2017
Abstract
Cushing’s syndrome remains an uncommon diagnosis with majority of non-specific and few specific clinical features 
suggestive of the condition. Results of biochemical investigations are often affected by confounding factors making 
diagnosis of Cushing’s syndrome difficult and localisation of the disease even more challenging. Careful assessment 
of the individual patient and use of the most suitable test in that patient may allow improved outcome in diagnosing 
and localising the condition to devise an appropriate management plan.
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Introduction
Patients with Cushing’s syndrome can present with varied 
signs and symptoms, but most patients are referred for 
screening in view of weight gain and unable to lose weight. 
Obesity is almost invariably present in Cushing’s syndrome 
but is of little diagnostic value due to its high prevalence in 
the population as a whole, particularly in women between 
the ages of 20 and 50 years who are the most likely age 
group to be suffering from Cushing’s syndrome.[1] Clinical 
acumen, however, is insufficient to establish the diagnosis, 
and confirmation depends on biochemical evidence of 
hypercortisolism using laboratory investigations. Since 
obesity is increasing at an alarming rate throughout the 
world (estimated >300 million obese people world-
wide),[2] the number of patients’ referrals for Cushing’s 
screening has also increased. Over the previous decade or 
so, there has been an increased awareness amongst general 
population about obesity-related complications and they 
are recognising obesity syndrome as a medical condition in 
itself which can adversely affect almost any system of the 
body. There has been a visible drive amongst obese patients 
and their primary care physicians who encourage them to 
lose weight. Cushing’s syndrome remains a rare diagnosis 
but is a potentially treatable condition and an important 
diagnosis to be considered in obese patients particularly 
those who have noticed a sudden increase in their weight 
and concentrated in central parts of their bodies and 
is resistant to dietary and pharmacological treatments. 
Although hypercortisolism can affect almost any system 
of the body, most patients are referred for Cushing’s 
screening for weight-related symptoms. Majority of such 
patients have not got Cushing’s syndrome, and screening 
tests are negative. Cushing’s syndrome is suspected on 
clinical symptoms and signs which is then confirmed or 
refuted with biochemical investigations. Imaging studies 
are required to localise the abnormality to help plan the 
management strategy. Most patients would have only 
one screening test, and only if it is positive or the results 
are not decisive, further investigations would be carried 
out. Localisation investigations are generally carried out 
if these screening tests confirm biochemical evidence of 
hyperocrtisolism.
A screening test is expected to pick up all the cases with 
a particular condition. A good screening test should have 
a high sensitivity. The test should be simple and easy to 
be performed, ideally on outpatient basis, and the results 
should be easy to interpret.[3] There is no single test which 
fulfills all these criteria;[4] however, high sensitivity is 
probably the most important criteria so that none of the 
patients with that particular condition are missed by a 
screening test . One would like all the investigations 
to be simple but investigations to screen patients for a 
rare disease where most of the results are expected to 
be negative should particularly be simple to allow most 
patients to undergo screening. Complex and cumbersome 
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investigations for screening rare conditions would not 
attract many patients. Cortisol level is measured in blood, 
urine and saliva to assess if it is being produced in excess. 
Overnight dexamethasone suppress test (ONDST), low-
dose dexamethasone suppression test (LDDST), midnight 
cortisol level (MCL), 24 h urine-free cortisol (24 h 
Manchester Royal Infirmary) assessment and salivary 
cortisol levels are usually run to screen patients for cortisol 
hypersecretion. In most patients, one or two of these 
screening tests are completed and further investigations 
are conducted if the results of these screening tests confirm 
hypercortisolism. Each of these screening tests has its 
limitations, and one may be the preferred investigation 
in a given clinical scenario.
Physiological Hypercortisolism
Cortisol is a steroid hormone synthesised from cholesterol 
in zona fasciculata of adrenal glands. Cortisol production 
in normal individuals is under the stimulatory effect of 
adrenocorticotropin hormone (ACTH) of the anterior 
pituitary gland, and ACTH production, in turn, is regulated 
by corticotropin-releasing hormone (CRH) of the 
hypothalamus. This stimulatory effect of CRH/ACTH is 
balanced by the inhibitory effect of cortisol by its negative 
feedback on CRH/ACTH production once there are 
sufficient levels of cortisol in blood circulation. Cortisol 
secretion follows a circadian rhythm with levels highest 
early in the morning and then continues to drop during the 
day. Its level is almost negligible at midnight (11 pm–2 
am)[5] before it starts to rise again from early morning. 
Cortisol production not only fluctuates during the day but 
it also fluctuates in response to environmental factors and 
individuals’ general health. Stressful situations are believed 
to increase cortisol levels and most patients in intensive 
care unit of a hospital will have high cortisol levels. This 
excessive production is transient and is essential for an 
individual to cope with the stressful situation. This state 
of hypercortisolism returns back to physiological range 
once the stimulus is over. The hypercortisolism does not 
need treatment in these conditions; however, the primary 
condition should be treated to reduce the duration of 
tissue exposure to high circulating level of cortisol. 
Ideally, cortisol level should not be assessed during these 
stressful conditions as a false positive rate of screening 
investigations is likely to be high and patients’ cortisol 
production should be assessed once patients are no longer 
in a stressful state. Once released in circulation, cortisol 
circulates predominantly bound to a protein called cortisol-
binding globulin (CBG) and albumin. In circulation, about 
90% of the cortisol circulates bound to CBG[6] and only 
<10% cortisol is circulating free.[4] CBG-bound cortisol 
serves as a reservoir and free cortisol is released to tissues 
locally for local metabolism.
Pathological Hypercortisolism
Prolonged and persistent exposure of tissues to high 
circulating cortisol level usually secondary to the pathology 
of CRH/ACTH or cortisol-producing organs leading to 
pathological changes in tissues is termed pathological 
hypercortisolism. The dynamic equilibrium of CRH/
ACTH and cortisol production is pathologically disturbed 
either by uncontrolled production of ACTH which then 
leads to excessive cortisol production (Cushing’s disease) 
or ACTH independent uncontrolled production of cortisol 
due to adrenal gland pathology (Cushing’s syndrome). 
For the sake of this manuscript, we will use the term 
Cushing’s syndrome to cover all of these (Cushing’s 
disease, ectopic CRH/ACTH production and Cushing’s 
syndrome). The production of CRH/ACTH and cortisol 
in these conditions is uncontrolled as pituitary gland and 
adrenal glands partially or completely no longer respond to 
the physiological mechanisms of stimulation and negative 
feedback inhibition. It is important to recognise that some 
patients of Cushing’s syndrome may partially respond and 
maintain negative feedback inhibition at higher cortisol 
levels in circulation. Majority of such patients are suffering 
from ACTH-dependant Cushing’s of pituitary origin. In 
majority of patients, Cushing’s syndrome is caused by 
pituitary tumours, adrenal tumours (benign and malignant), 
adrenal macronodular hyperplasia, bilateral primary 
pigmented nodular adrenal hyperplasia, part of McCune-
Albright syndrome and Carney’s complex.
Weight gain and obesity, proximal myopathy, 
hyperglycaemia and diabetes, hypertension, easy bruising, 
psychotic episodes and osteoporosis are some of the 
common symptoms and signs of hypercortisolism[7] as 
shown in Table 1.
Screening laboratory investigation for the diagnosis of 
Cushing’s syndrome is measurement of urinary free 
cortisol (UFC).
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24 h UFC used to be considered a gold standard test 
for hypercortisolism screening. Subsequently, some 
studies suggested that its sensitivity was not as good as 
it was thought and ONDST had better sensitivity than 
24 h UFC.[8] Ceccato et al. conducted a study in 2015 
and found that 24 h UFC achieves the best diagnostic 
accuracy compared with ONDST and MCL if processed 
properly using liquid chromatography with tandem mass 
spectrometry method.[9] It is a good screening test as this 
is an outpatient investigation and patient can collect urine 
at home and return the sample to laboratory once the 
collection is completed.
Once cortisol is released from adrenal glands in blood 
circulation, it circulates predominantly bound to CBG. 
The uncontrolled excessive production of cortisol in 
Cushing’s syndrome patients overwhelms available 
CBG and it starts circulating as free biologically active 
cortisol in blood circulation. CBG-bound cortisol stays in 
circulation as globulin is a large protein and is not filtered 
through glomerulus membrane during ultrafiltration, but 
the free cortisol (cortisol not bound to CBG) is filtered 
and excreted in urine. 24 h UFC is helpful in situations 
when CBG is high and total cortisol (CBG bound 
cortisol + free cortisol) is high due to high CBG-bound 
cortisol. 24 h UFC in these situations will show normal 
urinary cortisol levels as free cortisol is not high. CBG 
is high in patients taking oestrogen (contraceptive pill 
and hormone replacement therapy), drinking alcohol in 
excessive amounts, obesity and certain medicines.[11]. 
Since 24 h UFC depends on renal excretion of cortisol, 
this test becomes less reliable when renal functions are 
not normal (eGFR <60 ml/min) (10(13). In addition, high 
fluid intake, contamination and incomplete collection 
can also make the results unreliable.[10] One could use 
creatinine: Cortisol in such patients instead of total 24 h 
UFC. A high creatinine:cortisol ratio is suggestive of high 
circulating free cortisol levels. Creatinine level could also 
help to assess proper urine collection. Urine collection 
must be repeated if creatinine levels are <1.5g per day for 
men and <1g per day for women.[11] The test had a false-
positive rate of 3.3% and false-negative rate of 5.6% in 
pooled data of chronically ill, obese and non-obese 479 
individuals[12] Most laboratories use assays with normal 
cortisol level from 220 to 330 nmol/24 h (80–120 μg/24 h). 
It shows a sensitivity of 100% and specificity of 98%,[13] 
but a significant number of pseudo-Cushing’s syndrome 
patients have high urinary cortisol levels posing have high 
urinary cortisol levels posing a challenge in using this test 
alone to screen such patients.
Patients with 24 h UFC level more than 4 times the upper 
normal limit of 24 h UFC in the presence of clinical 
features of Cushing’s syndrome would not require any 
more biochemical investigations to confirm the diagnosis 
of Cushing’s syndrome. These patients should then undergo 
further investigations to localise the source of disease.
Cortisol secretion follows a circadian rhythm and its level 
is highest early in the morning and drops to minimal levels 
at night. Most patients with Cushing’s syndrome lose this 
circadian rhythm and do not tend to follow this pattern 
of cortisol secretion. Two separate small studies assessed 
cortisol levels in urinary samples collected between 
20:00–24:00 h and 22:00–23:00 h.[14,15] The results of these 
studies were encouraging, but there was a possibility of 
slight overlap between Cushing’s syndrome patients and 
Table 1: Signs, Symptoms and conditions associated 
with Cushing’s syndrome
Signs Symptoms Associated 
conditions
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very obese patients. These investigations can be of use in 
those patients where 24 h urine collection is not possible 
and other screening investigations cannot be used.
ONDST
In many endocrine disorders, dynamic endocrine tests are 
run to assess hyper- or hypo-secretion of a hormone. In 
most cases, one would need to try to suppress a particular 
hormone if suspecting hypersection of that hormone 
and to stimulate a hormone secretion when suspecting 
hyposecretion of that hormone. 1 mg dexamethasone 
tablet taken at 11 pm is expected to suppress CRH/ACTH 
secretion, and cortisol level should be <50 nmol/l in the 
blood sample collected at 8 am the following morning 
in normal individuals. 1 mg dexamethasone is expected 
to sufficiently raise steroid level in blood circulation to 
suppress CRH/ACTH production. Dexamethasone 1 mg 
should be taken at 11 pm as CRH/ACTH secretion starts 
to rise past midnight. CRH/ACTH secretion is inhibited in 
normal subjects by negative feedback if there are already 
sufficient steroids circulating in blood. Dexamethasone is 
not detected by assays used by most laboratories to assess 
cortisol level. This is a simple test and many patients 
prefer this over other screening tests. The reliability of 
the test relies on the sufficient rise in steroid levels in 
circulation following ingestion of 1 mg dexamethasone 
tablet. Dexamethasone is metabolised in liver, but there is 
interperson variability in normal subjects in metabolising 
dexamethasone. Slow metabolisers will have higher than 
required circulating levels of dexamethasone, and fast 
metabolisers may end up lower than required circulating 
dexamethasone levels. Dexamethasone levels should be at 
least >5.6 nmol/L (0.22 μg/dl) to ensure reliable results.[16] 
Serum dexamethasone levels should be assessed where 
such a facility is available; however, the availability of 
such an investigation is limited to a few centres only. To 
overcome this potential possibility of fast metabolism in 
some patients, it has been suggested that ONODST can be 
repeated with 2 mg dexamethasone in patients with negative 
test results with 1 mg dexamethasone and high clinical 
suspicion of Cushing’s syndrome. The test has a reported 
sensitivity of 97–100%[17] and specificity of 87.5%.[18]
MCL
This screening test is based on loss of circadian rhythm 
of cortisol secretion in patients of Cushing’s syndrome. 
Cortisol level is assessed in a blood sample collected 
at midnight. This test is not usually used as first-line 
screening test in majority of patients as patients are 
required to be admitted to hospital to collect blood sample 
at midnight. The sample has to be collected within 5 min 
of patient waking up or through a previously inserted 
indwelling catheter in case of awake patients[19] to avoid 
false-positive results. This is a good test to exclude 
Cushing’s syndrome, and if a patient achieves cortisol 
level <50 nmol/l on a midnight blood sample, they may 
not need any further investigations. The sensitivity of this 
test was found to be 100% in one study and in presence 
of clinical features may not require any further screening 
tests before localising investigations.[19]
LDDST
This test can be considered as a second-line investigation. 
This 48-h long test is usually performed once at least one 
of the screening tests has confirmed high cortisol level. In 
a total of eight doses, each of 0.5 mg dexamethasone is to 
be taken every 6 h and blood sample is collected 6 h after 
the last dose. In normal individuals, dexamethasone will 
suppress CRH/ACTH secretion, and cortisol level at the 
end of test will be <50 nmol/l. The reliability of the test 
is believed to be increased by longer exposure of CRH/
ACTH-producing organ to high cortisol blood levels. 
This test is believed to be 98% sensitive and specific for 
the diagnosis of Cushing’s syndrome. Since this test is 
more specific than other screening tests, a negative result 
would be strongly suggestive of the absence of Cushing’s 
syndrome in the patient. The test has a reported sensitivity 
and specificity of 97–100%.[17,20]
Localising Tests
ACTH assessment
Once biochemical investigations confirm pathological 
excessive production of cortisol, further investigations 
are focussed to find out if it is ACTH-dependant or ACTH 
in-dependant Cushing’s syndrome. Assessment of ACTH 
level in most cases is very helpful. Suppressed ACTH in 
the presence of high cortisol level is strongly suggestive 
of adrenal source; however, normal or high ACTH in the 
presence of high cortisol is suggestive of ACTH-dependant 
Cushing’s syndrome. It is recommended to assess ACTH 
levels on more than one occasion to confirm diagnosis 
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as some patients of pituitary Cushing’s syndrome can 
present with suppressed ACTH levels on some of their 
blood samples.[21,22] Imaging studies should be focussed on 
adrenal glands in patients with undetectable or suppressed 
ACTH levels. Normal or high ACTH level patients require 
further investigations to confirm the source of CRH/
ACTH to plan further management.
High-Dose Dexamethasone Suppression Test 
(HDDST)
This test is based on the belief that patients with pituitary 
Cushing’s syndrome respond to higher cortisol level in 
blood circulation and suppress CRH/ACTH secretion 
of pituitary gland leading to reduction in cortisol level 
circulation. The original test was performed by taking 
2 mg dexamethasone every 6 h over 48 h. Urinary 17 
hydroxycorticosteroid (17 OHCS) or UFC in a 24 h urine 
sample was used to assess the suppression in cortisol 
production from day 1 to day 3 of the test. Over time, 
only UFC was suggested to be assessed in urine samples 
as it was found as specific and sensitive as 17 OHCS. 
Subsequently, plasma cortisol level was recommended 
for assessment in HDDST although UFC and 17 OHCS 
can still be used. The sensitivity of HDDST with target 
of 90% reduction in UFC has been reported to be as low 
as 64% in some studies.[23]
48 h HDDST is complex and cumbersome. An 8-mg 
HDDST has been developed. Patient takes 8 mg 
dexamethasone at 23:00 h and blood samples are collected 
for cortisol level before dexamethasone intake and at 
08:00 h the following morning. A 50% reduction in plasma 
cortisol level achieved a sensitivity of 92% and sensitivity 
of 100%.[24] Since the test is much more convenient and 
provides better reliability of results it is replacing the 
traditional 48 h HDDST in most centres.
Inferior Petrosal Sinus Sampling
Assessment of ACTH gradient in samples collected from 
bilateral inferior petrosal sinuses which drain pituitary 
veins (central) and plasma (peripheral vein) helps to 
confirm the source of ACTH. In non-stimulated (basal) 
state, a ratio of ≥2 between central and peripheral plasma 
ACTH levels is considered diagnostic for pituitary 
Cushing’s disease.[25] Since some ectopic sources can 
produce a significant amount of ACTH and also pituitary 
ACH production can be episodic, stimulated samples 
are also collected. 100 ug CRH injection is given in a 
peripheral vein, and both central (inferior petrosal sinuses) 
and peripheral (peripheral vein) samples are collected at 3, 
5, 10 and 15 min. A stimulated ratio of ≥3 of ACTH levels 
in central and peripheral blood samples is considered 
diagnostic for pituitary Cushing’s disease.[26] Since the 
procedure is invasive and requires a high level of skill, 
this should be performed only at specific centres where 
such facilities are available and laboratory support can 
back this up.
Adrenal
Adrenal glands, one on top of each kidney, can produce 
excessive cortisol from zone fasiculata of either or both 
of adrenal glands with benign or malignant adrenal 
pathologies. Majority of cases have benign adrenal 
disease differentiated based on the morphology of adrenal 
glands on adrenal imaging. Unilateral or bilateral adrenal 
hyperplasia and adrenal adenomas are the benign adrenal 
pathologies responsible for Cushing’s syndrome. There 
has been a significant increase in incidental detection 
of adrenal pathology with a rise in imaging (computed 
tomography [CT] and magnetic resonance imaging 
scans) investigations of the abdomen. About 0.6–1.3% 
of abdominal CT scans detect adrenal lesions.[27] Adrenal 
adenoma remains the more common of the two causes 
of Cushing’s syndrome. So far, there are no risk factors 
or genes have been identified responsible for Cushing’s 
syndrome. Majority of such patients produce only 
cortisol and its metabolites in excess but some patients, 
especially with malignant adrenal lesions, may cosecrete 
excessive amounts of other adrenal hormones including 
adrenal androgens and its metabolites. Detection of these 
substances can help to identify the source of Cushing’s 
syndrome and plan further management accordingly.
Pituitary
ACTH is produced by basophilic corticotrophs of 
the anterior pituitary gland which constitute 20% of 
anterior pituitary gland cells. Pituitary ACTH-dependant 
Cushing’s constitutes up to 80% of all cases of Cushing’s 
syndrome.[28] Malignant lesions of the anterior pituitary 
gland are exceptionally rare and constitute <1% of all 
pituitary lesions. ACTH-producing pituitary lesions are 
notoriously small and challenging to be treated surgically. 
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Like any other pituitary lesion, ACTH-producing pituitary 
adenomas can either cosecrete other pituitary hormones 
and/or reduce production of other pituitary hormones due 
to pressure effects of adenoma on surrounding healthy 
pituitary cells. The initial biochemical investigations must 
include assessment of all hormones of the anterior pituitary 
gland in all such patients. This could help to confirm the 
source of the ACTH/CRH and further management plan.
Ectopic
ACTH production from sites other than pituitary gland 
or ACTH production from a pituitary gland under the 
influence of CRH produced from other than hypothalamus 
is termed as ectopic. In some patients, these ectopic 
sources produce metabolically active metabolites of 
ACTH which can still stimulate adrenal glands and 
produce Cushing’s syndrome. Many such patients may not 
have florid signs and symptoms of Cushing’s syndrome as 
they are usually diagnosed early on in the disease process, 
and usually with high levels of cortisol in circulation. 
Since this is not the case with all such patients, it cannot 
be used as a distinguishing feature of the condition. Since 
majority of such patients have very high cortisol level, 
they usually present with very low potassium. In majority 
of these patients, hypokalaemia is resistant and usually 
requires hospital admission for potassium replacement. 
Lung cancers are a common source of ectopic ACTH/
CRH production. Ectopic CRH is often produced by 
carcinoid tumours. Most such patients will produce other 
metabolites in addition to CRH/ACTH and detection 
of such substances in blood could help to localise the 
source of CRH/ACTH production. Pro-opiomelanocortin 
(POMC) precursors due to its partial processing and 
‘large ACTH’ due to its incomplete cleavage are found 
in patients with ectopic Cushing’s, especially, in patients 
of lung cancer. Detection of these molecules is suggestive 
although not diagnostic of ectopic Cushing’s as some 
pituitary adenomas may also have incomplete processing 
of POMC precursor and partial cleavage of ACTH due to 
their overproduction by pituitary tumour cells.[22,29]
At time, CRH/ACTH can be produced from sources 
other than pituitary gland (ectopic ACTH production) 
and can still stimulate adrenal glands to produce 
excessive uncontrolled amounts of cortisol, resulting in 
hypercortisolism.[30]
Cyclical Cushing’s
The excessive cortisol production can be continuous or 
cyclical. This episodic cortisol hypersecretion is often 
termed as cyclical Cushing’s and is usually more challenging 
to diagnose. Such patients have episodes of variable duration 
of excessive cortisol production separated by the episodes of 
normal cortisol production.[31] Such patients require cortisol 
assessment more than once in the presence of clinical signs 
and symptoms suggestive of hypercortisolism.
The presence of this type of Cushing’s syndrome 
necessitates an assessment of endogenous cortisol 
production on more than one occasion in patients suspected 
to have symptoms of Cushing’s syndrome. A significant 
change in psychological symptoms and behaviour is often 
the clue in such patients, and investigations should be 
completed during this episode.
Pseudo-Cushing’s
Pseudo-Cushing’s is a term used for conditions when 
patients have excessive endogenous production of 
glucocorticoids from adrenal glands in response to certain 
stimulating factors. The condition is potentially reversible 
and does not require treatment along the lines of Cushing’s 
syndrome. Such patients require treatment of other 
stimulating factors to bring endogenous glucocorticoid 
production within normal range. These patients present with 
signs and symptoms of Cushing’s syndrome. The severity 
and extent of symptoms and signs depend on the duration 
of tissues’ exposure to high levels of glucocorticoids and 
duration of those stimulating factors. Since the cortisol is 
being produced in excess, the laboratory screening tests 
are likely to show excessive cortisol production. It is 
important to recognise these factors and manage patients 
accordingly.[32] These factors are often termed as pseudo-
Cushing’s factors or states. These include depression, 
obesity, physical stress, malnutrition, eating disorders, 
polycystic ovarian syndrome, uncontrolled diabetes, 
obstructive sleep apnoea and chronic alcoholism.[33] In most 
cases, clinicians should try to address to these factors before 
considering screening for Cushing’s syndrome. The clinical 
manifestations of hypercortisolism should settle once these 
factors are controlled. Once these factors are well controlled 
and the patient still continues to experience symptoms and 
signs of Cushing’s syndrome, clinicians should then run 
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screening investigations for Cushing’s syndrome. Detection 
of alcohol in blood confirmed by blood alcohol level can 
help in such patients. Such patients should be admitted to 
ward to closely monitor for few days and MCL should drop 
to within normal range within 5 days in such patients.[34]
Iatrogenic Cushing’s
Patients requiring glucocorticoids for treatment of their 
medical conditions can develop iatrogenic Cushing’s 
syndrome due to prolonged exposure of tissues to 
supraphysiologic levels of glucocorticoids in blood 
circulation. The diagnosis in such patients is usually 
obvious with a history of use of glucocorticoids in 
therapeutic doses. Prednisolone and dexamethasone remain 
the two most commonly used oral agents in such patients. 
A significant number of patients using steroid inhalers on 
long-term basis may also suffer from this condition due 
to the absorption of inhaled steroid into blood circulation. 
Surreptitious ingestion of steroids in not commonly seen. 
Not all steroids are detected by commonly used laboratory 
assays. Undetectable ACTH levels along with undetected 
cortisol levels are strongly suggestive of surreptitious 
ingestion of steroids. This scenario would be encountered 
in patients ingesting the type of steroids not detected by 
laboratory assays. A similar picture would be expected with 
dexamethasone intake as dexamethasone is not detected 
by assays commonly used by laboratories for steroids.
Summary
Cushing’s syndrome remains a rare diagnosis but requires 
careful and systematic assessment and laboratory 
investigations. The diagnosis and localisation of the disease 
remain challenging in most patients although availability 
of ACTH levels has made it a bit easier. Patients with florid 
signs and symptoms and clear laboratory results may have 
management plans completely different from those who 
present early in their disease and laboratory results may 
not be diagnostic. In majority of patients, In majority of 
patients, Cushing’s syndrome is not caused by malignant 
lesions but carries high morbidity and mortality. Diagnosis 
must be considered in patients who may present with 
clinical features suggestive of the condition.
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